Get the Stockscreener App
12.63
1.10%
-0.14
After Hours:
12.88
0.25
+1.98%
Olema Pharmaceuticals Inc stock is traded at $12.63, with a volume of 1.60M.
It is down -1.10% in the last 24 hours and up +22.50% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$12.77
Open:
$12.95
24h Volume:
1.60M
Relative Volume:
1.18
Market Cap:
$1.10B
Revenue:
-
Net Income/Loss:
$-185.15M
P/E Ratio:
-6.2361
EPS:
-2.0253
Net Cash Flow:
$-148.72M
1W Performance:
+0.96%
1M Performance:
+22.50%
6M Performance:
-53.34%
1Y Performance:
+183.82%
1-Day Range:
$12.39
$13.09
1-Week Range:
$11.81
$13.09
52-Week Range:
$4.37
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
12.63 | 1.12B | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Peer Perform |
| Mar-19-26 | Resumed | Jefferies | Buy |
| Feb-11-26 | Initiated | Stifel | Buy |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Oncology awards 215,800 options to eight new employees - Stock Titan
Olema Pharmaceuticals (OLMA) Is Up 22.0% After Broad Russell Growth Index InclusionHas The Bull Case Changed? - simplywall.st
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story? - Yahoo Finance
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS: OLMA) added to Russell 2500 Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS: OLMA) added to Russell 2000 Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell 3000E Growth Benchmark - marketscreener.com
Olema Pharmaceuticals (OLMA) Holds Steady Near Support Amid Minor DeclineUp Down Volume - dars.gov.et
Olema Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:OLMA) - TradingView
OLMA Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Olema Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Australia
Olema (NASDAQ: OLMA) awards director 29,500 stock options - Stock Titan
BVF group (NASDAQ: OLMA) reports 29,500 new options and large pre-funded warrants - Stock Titan
Olema (NASDAQ: OLMA) director receives grant of 29,500 stock options at $9.51 - Stock Titan
Olema Pharmaceuticals (OLMA) director awarded 29,500 stock options at $9.51 strike price - Stock Titan
Olema (OLMA) director Garland J. Scott awarded 29,500 stock options at $9.51 - Stock Titan
[Form 4] Olema Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Olema Pharmaceuticals (OLMA) director granted 29,500 stock options at $9.51 strike - Stock Titan
Olema (OLMA) director receives 29,500 options at $9.51 strike price - Stock Titan
Olema (OLMA) director granted 29,500 stock options at $9.51 exercise price - Stock Titan
Olema (NASDAQ: OLMA) director granted 29,500 stock options at $9.51 strike price - Stock Titan
Olema (OLMA) director Graham Walmsley awarded 29,500 stock options at $9.51 - Stock Titan
Olema Pharmaceuticals (NASDAQ: OLMA) investors approve board slate, pay plan and Ernst & Young - Stock Titan
What Prompted the Chief Legal Officer's Recent OLMA Share Sales - Kavout
Olema Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Olema Pharmaceuticals Inc (OLMA) Institutional Confidence - TradingKey
Olema Pharmaceuticals Inc (OLMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Olema Pharmaceuticals Inc (OLMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Olema Pharmaceuticals Inc (OLMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Olema Pharmaceuticals Inc (OLMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Olema Pharmaceuticals Inc (OLMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet - Insider Monkey
10 Small Cap Stocks with Potential to Rise 1000 Percent - Insider Monkey
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
OLMA Stock Soars 47% in September So Far on Second PFE Deal - MSN
OLMA,GH Options - Finviz
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Olema Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
InvestingPro’s Fair Value flagged Olema stock as overvalued at $19.49 By Investing.com - Investing.com Canada
OLMA Q1 2026 Earnings: Narrower-Than-Expected Loss as Biotech Advances PipelineNegative Surprise Momentum - newsline.com
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
UBS Remains a Buy on Olema Pharmaceuticals (OLMA) - The Globe and Mail
OLMA Technical Analysis | Trend, Signals & Chart Patterns | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
A Look At Olema Pharmaceuticals (OLMA) Valuation After New Bayer Collaboration And OP-3136 Phase 1 Data - Sahm
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $24 - Moomoo
Guggenheim Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $35 - Moomoo
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):